A Phase I, Open Label, Dose Escalation Study of Immunoconjugate L-DOS47 in Combination with Vinorelbine and Cisplatin in Patients with Metastatic or Advanced Solid Tumours

Trial Profile

A Phase I, Open Label, Dose Escalation Study of Immunoconjugate L-DOS47 in Combination with Vinorelbine and Cisplatin in Patients with Metastatic or Advanced Solid Tumours

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs L-DOS 47 (Primary) ; Cisplatin; Vinorelbine
  • Indications Lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Helix BioPharma
  • Most Recent Events

    • 27 Oct 2017 According to a Helix BioPharma media release,company has insufficient supply of L-DOS47 to complete this study, so completion of the study will depend on the successful release and availability of new drug product.
    • 27 Oct 2017 According to a Helix BioPharma media release, once the MTD of the combination is determined, initiation of the randomization component of the study is anticipated in the second of 2018.
    • 27 Oct 2017 Status changed from planning to recruiting according to a Helix BioPharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top